PRM37 WX-III-287-19 A Possible Thromboxane Antagonist in Bovine Coronary Arteries  by Shah, A.J. et al.
A732  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 7 1 9 – A 8 1 3  
one that a new technology having the ICER smaller than L0 should not be accepted 
if the incremental effectiveness of the new technology is greater than the amount 
of Bmax divided by N times Lk. On the contrary, although the new technology can-
not be accepted (i.e., Lk > L0) under the conventional single-threshold approach, it 
should be accepted if the incremental effectiveness of the new technology is smaller 
than the amount of Bmax divided by N times Lk. ConClusions: Our approach 
offers multiple decision criteria for assessing a new health care technology with 
respect to the cost-effectiveness and its acceptability under the budget constraint. 
The theory which links single-ICER decision with budget impact has a potential 
to improve value-based decision making in government based on price-volume 
consideration of a new technology.
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PurPose: Evaluation of medical devices faces different challenges to that of the 
pharmaceutical drugs i.e., the approaches for cost-effectiveness modelling of phar-
maceutical drugs are not suitable for evaluation of devices. For example, the value 
of a device goes beyond the health benefits (i.e QALYs) to the patient as it might 
include other aspects such as increased efficiency, patient dignity, etc. Similarly, 
traditional cost modelling techniques are not suitable for evaluation of devices. 
The costs are not evenly spread across time and depend on implementation strate-
gies (i.e. parameters such as volume, scale, etc) and there is a need for a modelling 
framework that can output time profile of costs by stakeholder. Furthermore, the 
cost-effectiveness depends on the service setting (i.e. parameters such as volume 
and scale of deployment). Method: This presentation describes the lessons learnt 
while evlauating the cost-effectivess of diagnostic tests and devices. The details of 
the different projects are as follows a) Finanical modelling of telemonitoring for 
HF and COPD, b) Cost effectiveness of Cardiac Magnetic Resonance imaging for 
ischaemic cardiomyopathy, c) Cost-effectiveness of Telemonitoring technologies for 
congestive heart failure. result: A brief description of the context that makes HTA 
of medical devices of interest and characteristics of the devices that make them dif-
ferent from pharmaceutical drugs is detailed. An overview of current approaches of 
evaluating devices at different HTA bodies is provided. A taxonomy to represent the 
value of medical devices along with methods for incorporating patients’ preferences 
with examples of specific case studies. Finally, a financial modelling framework for 
evaluating devices that provides time profile of costs by stakeholder. ConClusion: 
Cost-effectiveness evaluation of medical devices is quite different to that of phar-
maceutical drugs. An overview of current methods for evaluation of devices and 
the issues involved are described along with a tentative  framework proposal for 
cost-effectiveness modelling of devices.
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Methods of a survey research in health have recently been included in an ethical 
review board in Thailand. A main goal of ethical consideration in health research 
is to protect the right and well-being of research participants, i.e., patients, villag-
ers and residents and to ensure the right and freedom of the research participants 
to corporate in a provision of research information.  The objective of this paper is 
to discuss loopholes of research methods in health and the discussions derived in 
part from a review board. A careful procedure of research methodology indicates 
the quality of research findings and provides a clue to the answer whether the 
results of research could be able for policy practices.  Methods ensure how health 
researchers are able to conduct the proper activities in seeking more truly research 
information from the participants . And the ethical review is to be certain how the 
personal information of the participants should be kept carefully. Loopholes in 
methods of health research were definitely lowering the quality of research prod-
ucts. Importantly, an application of research became questionable. Many loopholes 
were found in various steps of methodological application, including, setting an 
inclusion criteria, conducting an interview, utilizing research tool and more on 
stating research objectives and making a research title. The inclusion criteria of 
the research participants was specifically not inclusive, an interview usually held 
in hastezy environments  and improper mechanism for field research. Research 
tools applied were not carefully constructed and culturally inappropriate to the 
research subjects. Presenting a research protocol showed several inadequate train-
ing in methodological practices.
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Endothelium-dependent hyperpolarizations and relaxation of vascular smooth 
muscle induced by acetylcholine and bradykinin are mediated by endothelium-
derived hyperpolarizing factors (EDHFs). Arachidonic acid is metabolizedby 
cytochrome-P450 (CYP450) to four regioisomeric epoxyeicosatrienoic acids (EETs) 
that function as EDHFs.  5,6-, 8,9-, 11,12- and 14,15-EET are equipotent in relaxing 
bovine coronary arteries (BCAs). The miconazole analog, WX-III-287-19 was synthe-
sized and compared to EETsin causing relaxations of BCAs. EETs vascular relaxation 
responses were recorded using isometric tension recording.  BCA metabolism of 
20-H-11,12-EE8ZE was analyzed by mass spectrometry. In U-46619-preconstricted 
arterial rings, WX-III-287-19 caused concentration-dependent relaxation with 
maximal relaxation ranging from 95-100%; however, relaxations by 5,6-8,9-11,12 
and 14,15 EETs were less than WX-III-287-19. Preincubation of arteries with the 
a new part in terms of existing questionnaires – evaluates the homogeneity of 
the reported results and statistical methods, which are extremely important in 
preparing health technology assessment reports. At the moment the validation of 
developed scale is in progress – the results of evaluation will be presented at the 
conference. ConClusions: Improving standards of quality assessment of obser-
vational studies using the developed questionnaire, SQAROS, will help to obtain 
from these trials valuable scientific data on the effectiveness of health technologies.
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objeCtives: Evidence from real world are important for patients care. Pragmatic 
randomized control trial (PRCT) as one of the research methods of Comparative 
Effectiveness Research (CER) is used in many medical fields recently. This study 
aims to assess design and reporting qualities of PRCTs published in joint replace-
ment fields. Methods: We searched the Medline, Embase, CENTRAL to February 
2014 and the reference lists of retrieved studies to identify the full-report pragmatic 
randomized trials in English that compared Total Hip Replacement (THR) or Total 
Knee Replacement (TKR) with a conventional treatment. Three reviewers indepen-
dently assess the quality of PRCTs by using the pragmatic-explanatory continuum 
indicator summary (PRECIS) tool, CONSORT statement guidelines and the six CER 
defining characteristics of the Institute of Medicine (IOM). results: We screened 
55 potentially eligible abstracts and identified 6 full-text  PRCTs of joint replacement 
fields. Finally 3 trials with 4,152 patients were assessed. Three reviewers scored the 3 
trials based on PRECIS tool (39.5 vs 44 vs 36); CONSORT statement guidelines (36.5 vs 
39 vs 37.5); IOM defining characteristics of CER (26.5 vs 29 vs 29). All 3 trials reported 
the clinical, economic and patient-centered outcomes. The Knee Arthroplasty Trial 
with 10 years’ follow-up was scored the highest and considered to be more closer 
to the real world than other two trials as it was conducted in 2352 patients from 34 
UK centers and 116 surgeons in the study could adjusted their treatments based on 
individual patients’ characteristics. ConClusions: PRCT is different from stand-
ard RCT in many aspects. The number of PRCT in joint replacement field is limited 
and the quality need to be improved. PRECIS, CONSORT guidelines are useful for 
researchers in designing and reporting the PRCT.
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objeCtives: To determine the best algorithm for using the GRACE checklist to 
rate the quality of observational comparative effectiveness research (CER) stud-
ies. Methods: An 11-item checklist about data and methods was developed 
through literature review and consultation with experts. The checklist was applied 
to 88 articles by 113 raters from 5 continents, and their feedback helped shape 
questions and user guidance. Positive and negative predictive values (PPV and NPV, 
respectively) were calculated based on a volunteer rater’s assessment of a published 
article compared to a “gold standard” as determined through an article’s inclusion in 
a systematic review or through expert assessment. Multivariate regression analysis 
and Classification and Regression Trees (CART) analysis will be conducted based on 
data collected from 22 volunteer raters’ assessment of 28 articles of comparative 
effectiveness using a revised version of the checklist. results: Checklist items 
pertaining to data have relatively strong NPV, meaning the checklist is effective 
in identifying CER articles of insufficient quality. The single best performing item 
was the validity of the primary outcome, which achieved NPV and PPV ≥ 0.67 in 
four rounds of testing. Question items pertaining to whether the primary outcome 
was measured objectively and adequately recorded also achieved high NPV (≥ 0.67 
in 4 and 5 rounds of testing, respectively). Other indicators of quality include the 
use of concurrent comparators (NPV ≥ 0.67 in 5 rounds of testing). ConClusions: 
Univariate analyses have demonstrated the usefulness of the checklist items to 
screen out articles of insufficient quality for decision support. Results of multi-
variate analyses as used to develop 1) a parsimonious model to identify which 
checklist items can best be used as a quick screening tool and 2) a regression tree 
that maximizes the NPV of the checklist will be presented.
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objeCtives: To develop multiple decision criteria for assessing cost-effectiveness 
of a new health care technology under the budget constraint often experienced in 
government managing the national health insurance system. Methods: Let Lk, 
L0, Bmax, and N be, respectively, the ICER of a new technology compared to its com-
parator, the cost-effectiveness threshold for acceptance of any new technology on 
reimbursement decision, maximal increment of the government budget caused by 
the new technology, and the population-size targeted for the new technology. Based 
on those parameters, the mathematical relations among them were theoretically 
developed, formulated and graphically represented on the 2-dimensional plane of 
incremental cost and effectiveness. results: The single-threshold decision mak-
ing defined in pharmacoeconomics is that the ICER, Lk, of a new technology can 
be accepted if and only if Lk is smaller than the pre-defined ICER threshold, L0. We 
proved, however, this conventional decision should be changed into more complex 
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pared to well-moderately differentiated tumor (p = 0.0172). Having poorly differenti-
ated tumor was related to higher death rate immediately after diagnosis, but this 
disadvantageous effect gradually vanished over time. Fourteen comorbidity con-
ditions were significantly associated with shorter time-to-death. ConClusions: 
Effective control of comorbidity in PCa patients should help improve life expectancy 
and lead to prolonged survival. Further research is needed to understand mecha-
nisms in which individual and contextual factors impact PCa survival.
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objeCtives: Bevacizumab is a humanized monoclonal antibody that produces 
angiogenesis inhibition by inhibiting vascular endothelial growth factor A (VEGF-A). 
Bevacizumab was approved for combination use with standard chemotherapy for 
metastatic colon cancer. This research aims to conduct a systematic review on 
meta-analysis and cost-effectiveness analysis on standard chemotherapy plus 
bevacizumab for patients with metastatic colorectal cancer (mCRC) to explore the 
efficacy, safety and cost-effectiveness on the addition of bevacizumab. Methods: 
A systematic literature search on both meta-analysis and cost-effectiveness analy-
sis of chemotherapy plus bevacizumab on databases was carried out in several 
databases, such as MEDLINE, PubMed, CNKI chemotherapy. Articles were included 
based on specific inclusion and exclusion criteria. results: Six included analyses 
indicate that chemotherapy plus bevacizumab significantly prolonged progression-
free survival (PFS) and overall survival (OS). The risk of hypertension, bleeding and 
proteinuria are significantly increased, whereas there are no significant differences 
on gastric perforation, thrombosis. Eleven cost-effectiveness analysis demonstrate 
that the addition of bevacizumab lead to higher medical cost and health care cost. 
In most countries involved in this review, chemotherapy plus bevacizumab is not 
cost-effective comparing with standard chemotherapy. However, the medical and 
health care cost of using bevacizumab is lower than cetuximab. ConClusions: 
The addition of bevacizumab significantly increases survival benefits and slightly 
leads to more adverse events. Due to higher cost of bevacizumab, it is not cost-
effective therapy for mCRC patients. According to the potential considerable differ-
ences on economic status, epidemiology, clinical effectiveness, the generalizability 
of included meta-analyses and cost-effectiveness analyses need to be taken into 
account. Analyses based on China local data should be processed in the future.
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objeCtives: This study assessed whether sequential treatment of chemotherapy 
with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) ver-
sus chemotherapy alone as the first-line therapy improved treatment outcomes 
in patients with advanced non-small cell lung cancer (NSCLC) who do not receive 
EGFR gene testing in the resource-limited care setting. Methods: We searched 
seven databases up to November 30th, 2013. Randomized controlled trials (RCTs) 
were included. Pre-specified outcomes included progression-free survival (PFS), 
overall survival (OS), objective response rate (ORR), quality of life (QoL) and adverse 
events. Two investigators independently selected studies, assessed the risk of bias, 
and collected data. results: Four trials involving 1,274 patients were eligible for 
inclusion. If treated unselectively, sequential therapy significantly increased PFS 
(hazard ratio[HR] 0.59, 95% CI 0.49-0.71), OS (HR 0.85, 95% CI 0.75-0.97), and ORR (risk 
ratio[RR] 2.03, 95% CI 1.46-2.84) in NSCLC patients. However, the benefits appeared to 
be achieved in patients with EGFR M+ NSCLC (PFS: HR 0.25, 95% CI 0.16-0.39; OS: HR 
0.48, 95% CI 0.27-0.85; and ORR: RR 5.74, 95% CI 2.86-11.50), but not in patients with 
EGFR-WT NSCLC (PFS: HR 0.97, 95% 0.69-1.36; OS: HR 0.77, 95% 0.53-1.11; and ORR: RR 
0.74, 95% 0.41-1.34). Sequential therapy caused more skin rash (5.19% vs. 0.63%; RR 
7.36, 95% CI 2.79-19.44). Nevertheless, there was no statistically significant difference 
between groups in other adverse events. ConClusions: Although sequential use 
of chemotherapy and EGFR-TKI as first line therapy seemed to improve effects in 
NSCLC patients who did not receive gene testing, the apparent benefits were primar-
ily attributable to the improvement in patients who had EGFR M+ cancer. Due to the 
limited power of study, the sequential therapy does not appear to improve treat-
ment outcomes in patients with EGFR-WTcancer. Randomized trials that specifically 
address the effect of sequential therapy in advanced NSCLC patients are warranted.
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objeCtives: In China, the annual number of cervical cancer (CC) cases is expected 
to increase between 42,000 and 187,000 in 2050. Previous meta-analysis reported 
gestational history and sexual behaviour as the main risk factors for CC in China. 
This study aims at updating these findings with a comprehensive systematic lit-
erature review. Methods: The systematic literature review retrieved citations 
from MEDLINE, MEDLINE-IN-PROCESS and EMBASE, and three Chinese databases, 
CNKI, Wanfang Data and CQVIP, using PICOS framework. The target population 
was Chinese adolescent or adult females. All observational studies irrespective 
of intervention or comparator reporting risk factors for CC were included. Search 
EET antagonist,14,15-EEZE (10-5 M) did not inhibit relaxation to WX-III-287-19, but 
inhibited relaxation to 5,6-8,9-11,12 and 14,15 EETs. Preincubation with the ibe-
riotoxin (10-5 M) only partially inhibited the relaxation induced by WX-III-287-19 
whereas high K+  (60 mM) significantly inhibited relaxation to WX-III-287-19. In 
whole cell-attached patches of isolated bovine coronary arterial smooth muscle 
cells, WX-III-287-19 did not alter activation of large-conductance, calcium-activated 
K+ channels.In U-46619-preconstricted rabbit aortic rings, WX-III-287-19 caused 
relaxation; however, relaxations were not observed in arteries preconstricted with 
either high K+ (60 mM) and pheynylephrine (10-5 M). These results indicate that 
WX-III-287-19 is a potent coronary vasorelaxant and may act as a thromboxane 
receptor antagonist.
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During the development of society and the economy, the rapid growth of health care 
costs has become a burden on the worldwide health protection system. The problem 
of aging populations and a changing disease spectrum as well as the progress and 
change in health care technology, therefore, the health care costs increased. The 
major problem of many countries is how to use drug utilization review (DUR) and 
pharmacoeconomic evaluation to improve and optimize the configuration of medi-
cal and health resources. This paper presents the importance of drug utilization 
review and pharmacoeconomic evaluation and discusses the application of them 
in new drug research and development, drug pricing, the selection of NRDL, and 
promoting rational drug use. The quality of drug utilization review and pharmaco-
economic evaluation is critical. Furthermore, this paper analyzes problems and chal-
lenges of drug utilization review and pharmacoeconomic evaluation. Government 
departments, medical institutions, pharmaceutical companies, and research insti-
tutes should use them to solve their problems. Key words:  Drug utilization review, 
Pharmaoeconomic evaluation, Pharmacoeconomics.
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objeCtives: To review prevalence and risk factors of febrile neutropenia in breast 
cancer patients received adjuvant paclitaxel treatment. Methods: retrospective 
chart review of 18 breast cancer patients received 146 cycles of adjuvant paclitaxel 
for prevention of breast cancer recurrence during 2011 at Phramongkutklao hospi-
tal, Bangkok, Thailand results: Average age of patient in this study was 54.6+/-10.5 
years old. Paclitaxel were given to patients in 7 dosage regimens. The most common 
dosage regimen (62/146, 42.5%) was weekly paclitaxel 12 cycles post doxorubicin and 
cylcophosphamide (AC) regimen. There were 3 febrile neutropenia cases out of 18 
patients who recieved 154 cycles of adjuvant paclitaxel treatment. Prevalence of febrile 
neutropenia in this study was 2.05%. Prevalence of neutropenia in this study was 7.5% 
(11 cases out of 146 treatment cycles). Dosage regimen of paclitaxel (> 100 mg/m2 /cycle 
) associated with neutropenia was found to associated with neutropenia. Other com-
mon adverse events found in this study were peripheral neuropathy in 9 cases (50%), 
nausea/vomiting 7 cases (29%) and muscle weakness 6 cases (25%). ConClusions: 
Neutropenia from higher dose (> 100 mg/m2) of paclitaxel was common and trend to 
associated with febrile neutropenia in breast cancer patients treated with this drug. 
Closely monitoring and supportive therapy is needed in the patients recieving higher 
paclitaxel dose to prevent febrile nutropenia during adjuvant paclitaxel treatment.
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objeCtives: Few studies have looked at the independent contribution that individ-
ual-level and contextual factors make to prostate cancer (PCa) survival. The aim is to 
investigate individual and contextual factors contributing to overall PCa survival in 
Florida. Methods: A random sample of 6453 cases diagnosed with prostate cancer 
between 10/1/2001 and 12/31/2007 in the Florida Cancer Data System provided data 
on: individual demographics and clinical information. Census 2000 was linked to 
patient data. Comorbidity was computed following Elixhauser Index. Estimated 
survival probability curve was generated using the Kaplan-Meier estimator. Wei, 
Lin and Weissfeld (WLW) survival model was adopted for the multivariate analysis. 
The observation times were censored at June 30, 2012 for patients who were alive 
at end of study. results: Range of observation period was 5 to 3925 days, where 
1100 patients (17.05%) died. Older diagnosis age was associated with shorter time-to-
death. Overall death rate for African American patients was 14.3% higher than that 
of Caucasian patients, although this relationship was not significant (p = 0.2305). 
Uninsured patients had a 66.7% higher mortality rate than that of patients holding 
private insurance (p = 0.0351). Current smokers had a 62.4% higher mortality rate 
than that of non-current smokers (p < 0.0001). Higher hazard of overall mortality 
was associated with being diagnosed with advanced stage compared to localized 
stage (HR = 1.89, p < 0.0001) and having undifferentiated or unknown tumor com-
